Profile data is unavailable for this security.
About the company
Nano Holdings Inc is a Japan-based company mainly engaged in the micellar nanoparticle technology to develop innovative pharmaceuticals, focusing on anticancer drugs that encapsulate small molecule drugs within nanoparticles. The Company operates through a single segment encompassing the research and development, manufacturing, and sales of pharmaceuticals and related services. The Company conducts non-clinical and early-stage clinical trials, then licenses the resulting development candidate assets to pharmaceutical companies, thereby developing an RNA drug discovery business that efficiently brings RNA medicines to the market. In promoting RNA drug discovery, the Company leverages its experience in drug delivery system anticancer drug development and manufacturing, nucleic acid drug research and development, and a variety of DDS selection options based on this experience, creating and licensing assets that enable rapid progress in pharmaceutical development.
- Revenue in JPY (TTM)156.34m
- Net income in JPY-887.50m
- Incorporated1996
- Employees20.00
- LocationNano Holdings IncOhnoya Kyobashi Bldg., 1-4-10, KyobashiMINATO-KU 105-6226JapanJPN
- Phone+81 364324791
- Fax+81 364324794
- Websitehttps://www.nanomrna.co.jp/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tsubota Laboratory Inc | 710.56m | -398.77m | 6.91bn | 17.00 | -- | 6.25 | -- | 9.73 | -15.53 | -15.53 | 27.55 | 42.86 | 0.3594 | 0.4522 | 50.46 | 41,797,700.00 | -20.17 | 0.1041 | -29.56 | 0.1517 | 81.65 | 71.43 | -56.12 | 0.2216 | 2.60 | -- | 0.0634 | 0.00 | 101.49 | 25.17 | 132.08 | 132.70 | 26.42 | -- |
| Linical Co Ltd | 9.32bn | -1.77bn | 7.82bn | 598.00 | -- | 1.26 | -- | 0.8389 | -78.51 | -78.51 | 412.61 | 251.02 | 0.5937 | -- | 3.62 | 15,584,280.00 | -11.30 | 2.59 | -20.50 | 4.19 | 17.48 | 29.24 | -19.03 | 3.74 | -- | -192.93 | 0.2933 | 77.26 | -15.20 | -0.9283 | -259.37 | -- | -42.01 | 4.24 |
| OncoTherapy Science, Inc. | 784.25m | -881.65m | 7.91bn | 47.00 | -- | 3.70 | -- | 10.09 | -2.93 | -2.93 | 2.60 | 5.68 | 0.4224 | 8.38 | 8.72 | 16,686,090.00 | -47.48 | -63.66 | -56.22 | -77.43 | 3.63 | -0.3852 | -112.42 | -184.75 | 8.13 | -832.79 | 0.0043 | -- | 22.93 | 18.86 | 36.71 | -- | -70.80 | -- |
| PRISM BioLab Co Ltd | 684.61m | -927.75m | 8.16bn | 35.00 | -- | 3.35 | -- | 11.92 | -25.27 | -25.27 | 18.64 | 66.06 | 0.1886 | -- | 8.79 | 19,560,140.00 | -25.55 | -- | -32.06 | -- | 38.47 | -- | -135.52 | -- | -- | -77.05 | 0.00 | -- | 121.62 | -- | 20.56 | -- | -- | -- |
| Medinet Co Ltd | 787.09m | -1.36bn | 8.27bn | 107.00 | -- | 2.39 | -- | 10.50 | -5.12 | -5.12 | 2.97 | 12.95 | 0.1701 | 11.08 | 3.00 | 7,355,991.00 | -29.29 | -22.42 | -31.04 | -23.64 | 13.58 | 17.68 | -172.25 | -173.59 | 11.33 | -- | 0.00 | -- | 5.44 | 0.6867 | -6.67 | -- | 10.06 | -- |
| Chiome Bioscience Inc | 593.29m | -982.78m | 8.61bn | 47.00 | -- | 7.56 | -- | 14.52 | -14.48 | -14.48 | 8.74 | 16.39 | 0.2828 | 4.97 | 9.64 | -- | -46.84 | -52.22 | -59.06 | -64.41 | 59.93 | 57.59 | -165.65 | -174.88 | 3.99 | -1,177.61 | 0.1891 | -- | -24.02 | 4.29 | 3.72 | -- | -- | -- |
| Chordia Therapeutics Inc | 0.00 | -1.46bn | 8.82bn | 20.00 | -- | 3.70 | -- | -- | -21.23 | -21.23 | 0.00 | 32.67 | 0.00 | -- | -- | 0.00 | -46.77 | -- | -49.97 | -- | -- | -- | -- | -- | -- | -222.95 | 0.00 | -- | -- | -- | 2.26 | -- | -- | -- |
| BrightPath Biotherapeutics Co Ltd | 1.11m | -1.08bn | 9.49bn | 24.00 | -- | 5.25 | -- | 8,547.08 | -11.59 | -11.59 | 0.0117 | 13.70 | 0.0007 | -- | -- | 46,250.00 | -63.35 | -59.65 | -74.36 | -63.78 | 97.66 | 73.74 | -96,860.36 | -28,727.67 | -- | -1,103.91 | 0.00 | -- | 1,473.61 | -36.87 | 1.45 | -- | -58.41 | -- |
| Kidswell Bio Corp | 7.06bn | 23.83m | 13.29bn | 37.00 | 234.12 | 6.90 | 543.30 | 1.88 | 1.14 | 1.14 | 150.11 | 38.83 | 1.30 | 6.38 | 23.34 | 190,934,200.00 | 0.4375 | -16.75 | 0.678 | -27.06 | 27.45 | 47.46 | 0.3374 | -28.29 | 2.76 | -- | 0.5768 | -- | 109.03 | 36.37 | 98.51 | -- | 27.20 | -- |
| Nano Holdings Inc | 156.34m | -887.50m | 13.66bn | 20.00 | -- | 4.95 | -- | 87.38 | -12.46 | -12.46 | 2.19 | 36.19 | 0.0308 | 44.49 | 5.29 | 7,817,050.00 | -17.51 | -23.68 | -22.01 | -25.37 | 89.54 | 82.69 | -567.67 | -746.83 | 5.93 | -- | 0.4829 | -- | -19.92 | -27.80 | -7.10 | -- | -- | -- |
| Pharma Foods International Co., Ltd. | 66.38bn | -1.88bn | 18.35bn | 613.00 | -- | 1.94 | -- | 0.2764 | -64.99 | -64.99 | 2,293.41 | 324.90 | 2.02 | 1.70 | 15.01 | 108,280,600.00 | -5.74 | 6.92 | -16.01 | 18.90 | 80.32 | 80.70 | -2.84 | 3.34 | 0.6512 | -8.21 | 0.6151 | 33.24 | 5.01 | 33.56 | -88.52 | -11.84 | -0.161 | 24.08 |
| Holder | Shares | % Held |
|---|---|---|
| Simplex Asset Management Co., Ltd.as of 05 Feb 2026 | 176.70k | 0.23% |
